Scientists identify key biomarkers that reliably predict response to immune checkpoint inhibitor therapy for melanoma

Currently, the only FDA approved biomarker for ICI melanoma treatment is the tumor mutation burden assay, but the mechanisms linking it to ICI remain unclear. However, new research now provides evidence of novel, reliable biomarkers that predict therapy response using advanced computer technology.

Leave a Comment